Bone turnover markers in HIV-infected women on tenofovir-based antiretroviral therapy

Bone turnover markers in HIV-infected women on tenofovir-based antiretroviral therapy

Background: Tenofovir disoproxil fumarate (TDF) antiretroviral therapy is associated with disruption of the bone turnover process. Objectives: The objective of this study was to determine the association between tenofovir (TFV) plasma concentration and various bone turnover markers and compare thes...

Full description

Bibliographic Details
Main Authors:	Mwila Mulubwa, Michelle Viljoen, Iolanthe M. Kruger, Herculina S. Kruger, Malie Rheeders
Format:	Article
Language:	English
Published:	AOSIS 2017-12-01
Series:	Southern African Journal of HIV Medicine
Subjects:	Tenofovir levels Bone turnover markers Female HIV-infected
Online Access:	https://sajhivmed.org.za/index.php/hivmed/article/view/739

Similar Items

Associations between plasma tenofovir concentration and renal function markers in HIV-infected women
by: Mwila Mulubwa, et al.
Published: (2016-07-01)

Increase in bone turnover markers in HIV patients treated with tenofovir disoproxil fumarate combined with raltegravir or efavirenz
by: Yonatan Oster, et al.
Published: (2020-12-01)

Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV
by: Nicole Marie Lioufas, et al.
Published: (2018-06-01)

Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir
by: Daniel Yilma, et al.
Published: (2020-08-01)

Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study
by: Mahoko Ikeda, et al.
Published: (2021-05-01)

Association of Tenofovir Use With Risk of Incident Heart Failure in HIV‐Infected Patients
by: Ruijun Chen, et al.
Published: (2017-04-01)

Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort
by: Chua Arlene C, et al.
Published: (2012-06-01)

Diabetes, biochemical markers of bone turnover, diabetes control and bone
by: Jakob eStarup-Linde, et al.
Published: (2013-03-01)

Long-Term Evaluation of Changes in Kidney Function after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients Living with HIV
by: Jared M. Gilbert, et al.
Published: (2022-11-01)

Factors Associated with Bone Mineral Density and Bone Resorption Markers in Postmenopausal HIV-Infected Women on Antiretroviral Therapy: A Prospective Cohort Study
by: Christa Ellis, et al.
Published: (2021-06-01)

Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor
by: Patricia Llamas-Granda, et al.
Published: (2021-10-01)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
by: Sarah M Michienzi, et al.
Published: (2021-07-01)

Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
by: Margaret O. Ilomuanya, et al.
Published: (2020-11-01)

Tenofovir-Containing Antiretroviral Therapy and Clinical Outcomes of SARS-CoV-2 Infection in People Living with HIV
by: María F. Rombini, et al.
Published: (2023-05-01)

A longitudinal study of renal function outcomes in a cohort of HIV patients on tenofovir-based antiretroviral therapy in Ashanti region, Ghana
by: E. Ahenkan, et al.
Published: (2023-07-01)

Lipid levels, insulin resistance and cardiovascular risk over 96 weeks of antiretroviral therapy: a randomised controlled trial comparing low-dose stavudine and tenofovir
by: Alinda G. Vos, et al.
Published: (2018-12-01)

Assessing bone mineral density in children and adolescents living with HIV and on treatment with tenofovir disoproxil fumarate: a systematic review
by: Maria Brennda Ferreira de Gusmão, et al.
Published: (2023-11-01)

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles
by: Hung-Yao Lin, et al.
Published: (2022-04-01)

Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections
by: Erik De Clercq
Published: (2021-12-01)

Evaluation of cardiovascular biomarkers In HIV-infected patients switching to abacavir or tenofovir based therapy
by: Langdahl Bente L, et al.
Published: (2011-10-01)

Bone turnover markers: Emerging tool in the management of osteoporosis
by: Sahana Shetty, et al.
Published: (2016-01-01)

Correlations between bone turnover markers, serum magnesium and bone mass density in postmenopausal osteoporosis
by: Mederle OA, et al.
Published: (2018-08-01)

Renal function and lipid metabolism in Japanese HIV-1-positive individuals 288 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate: a single-center, retrospective cohort study
by: Kensuke Abe, et al.
Published: (2024-02-01)

Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis
by: Aoran Luo, et al.
Published: (2018-09-01)

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
by: Nicholas T. Funderburg, et al.
Published: (2016-11-01)

Adenosine Deaminase as a Biomarker of Tenofovir Mediated Inflammation in Naïve HIV Patients
by: Francisco Miguel Conesa-Buendía, et al.
Published: (2020-05-01)

Release of Tenofovir from Carrageenan-Based Vaginal Suppositories
by: Toral Zaveri, et al.
Published: (2014-07-01)

Bone turnover markers in epileptic patients under chronic valproate therapy
by: Mohammad Zare, et al.
Published: (2013-01-01)

Synthesis and Evaluation of Anti-HIV Activity of Mono- and Di-Substituted Phosphonamidate Conjugates of Tenofovir
by: Aaminat Qureshi, et al.
Published: (2022-07-01)

Corrigendum: The role of drug transporters in the kidney: lessons from tenofovir
by: Darren eMoss
Published: (2015-02-01)

Hypophosphatemic osteomalacia associated with tenofovir: a multidisciplinary approach is required.
by: Giuseppe Vittorio De Socio, et al.
Published: (2012-05-01)

Comprehensive Study of Antiretroviral Drug Permeability at the Cervicovaginal Mucosa <i>via</i> an In Vitro Model
by: Constandinos Carserides, et al.
Published: (2022-09-01)

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate in a cohort of patients with HBV infection: A retrospective study
by: Giacomo Stroffolini, et al.
Published: (2024-02-01)

Prevalence and factors associated with renal dysfunction in patients on tenofovir disoproxil fumarate-based antiretroviral regimens for HIV infection in Southern India
by: Nagalingeswaran Kumarasamy, et al.
Published: (2018-01-01)

Tenofovir-Diphosphate as a Marker of HIV Pre-exposure Prophylaxis Use Among East African Men and Women
by: Maria Pyra, et al.
Published: (2019-04-01)

Early switching of tenofovir disoproxil fumarate (TDF) in HIV-infected patients with TDF-induced nephrotoxicity: a prospective study
by: Samadhi Patamatamkul, et al.
Published: (2022-12-01)

Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: A retrospective observational study
by: Thomas C.S. Martin, et al.
Published: (2020-11-01)

Effects of Alendronate and Raloxifene on Bone Density and Bone Turnover Markers in Postmenopausal Women
by: Ebru Zülfikaroğlu, et al.
Published: (2011-04-01)

Fanconi Syndrome Leading to Hypophosphatemic Osteomalacia Related to Tenofovir Use
by: Mana Rao, et al.
Published: (2021-05-01)

Distribution Evaluation of Tenofovir in the Breast Milk of Mothers With HBeAg-Positive Chronic HBV Infection After Treatment With Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate by a Sensitive UPLC-MS/MS Method
by: Na Yang, et al.
Published: (2021-08-01)